Influence of Genetic Polymorphism on Dose-Dependent Analgesic Response and Safety to Propofol in General Anesthesia
Summary
This ClinicalTrials.gov entry registers a new observational study (NCT07543523) investigating how genetic polymorphisms in drug-metabolizing enzymes — CYP2B6, CYP2C9, and UGT1A9 — affect individual patient response to propofol, a widely used intravenous anesthetic. The study will enroll patients undergoing general anesthesia and assess outcomes including induction time, recovery time, and adverse-effect profiles across poor and altered metabolizer phenotypes. Study interventions include Propofol Group and Isoflurane Group assignments, with conditions focused on analgesia.
“This study investigates the influence of genetic polymorphisms in key drug-metabolizing enzymes-CYP2B6, CYP2C9, and UGT1A9-on the individual response to propofol, a widely used intravenous anesthetic, in patients undergoing general anesthesia.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.
What changed
This ClinicalTrials.gov registration entry documents a new observational study examining the pharmacogenomic basis of inter-individual variability in propofol response. The trial focuses on three key drug-metabolizing enzymes — CYP2B6, CYP2C9, and UGT1A9 — and their association with induction time, recovery time, and adverse effect profiles in patients receiving general anesthesia.
For clinical research sponsors and healthcare institutions: this trial reflects growing interest in genotype-guided anesthesia protocols. Sites conducting perioperative pharmacogenomics research or developing personalized sedation protocols may wish to monitor recruitment outcomes and any published findings regarding metabolizer phenotype-based dosing adjustments.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
The Influence of Genetic Polymorphism on Dose- Dependent Analgesic Response and Safety to Propofol in General Anesthesia
N/A NCT07543523 Kind: NA Apr 22, 2026
Abstract
This study investigates the influence of genetic polymorphisms in key drug-metabolizing enzymes-CYP2B6, CYP2C9, and UGT1A9-on the individual response to propofol, a widely used intravenous anesthetic, in patients undergoing general anesthesia. Despite propofol's fast onset and favorable recovery profile, significant inter-individual variability exists in its dosing requirements, sedation depth, and adverse effects. Such variability is believed to arise in part from genetic differences that affect drug metabolism and action. This research focuses on identifying how specific gene variants, particularly those linked to poor or altered metabolizer phenotypes, influence clinical outcomes like induction time, recovery time, and safety profiles during anesthesia.
Conditions: Analgesia
Interventions: Propofol Group, Isoflurane Group
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.